Gubra A/S (GUBRF)

Market Cap	953.03M +4.7%
Revenue (ttm)	414.54M +892.2%
Net Income	265.78M
EPS	16.15
Shares Out	n/a
PE Ratio	3.59
Forward PE	33.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	60.15
Previous Close	60.15
Day's Range	60.15 - 60.15
52-Week Range	60.15 - 102.41
Beta	0.32
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Gubra

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinfor...

• Industry: Commercial Physical and Biological Research
• Founded: 2008
• Employees: 300
• Stock Exchange: OTCMKTS
• Ticker Symbol: GUBRF

Financial Performance

Financial numbers in DKK

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Aug 11, 2026

Data Sources Report a data error